We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The marketing application (acceptance No. JXSS1900025) of a new indication of Novartis’ secukinumab in China has recently changed to “Under approval” and is expected to be approved soon. First approved by the NMPA for marketing in Mar. 2019, this will be